

CSD/BM/SE/2026-27

Date: May 13, 2026

**To**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Outcome of the Meeting of Board of Directors**

.....

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 13, 2026, has inter-alia considered and approved the following along with other business matters:-

**1. Audited Financial Results (Standalone and Consolidated)**

Took on record and approved the attached Audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and financial year ended March 31, 2026 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Audit Reports of the Statutory Auditors.

**2. Annual General Meeting (AGM)**

Notice convening the 37<sup>th</sup> Annual General Meeting of the Company scheduled to be held on Tuesday, 25<sup>th</sup> August, 2026 through video conferencing (VC)/ other audio-visual means (OAVM).

**3. Noting of fines levied by BSE and NSE and waiver of the same by the exchanges**

The Board noted the acceptance of waiver of fines by BSE, as communicated vide email dated April 23, 2026, in respect of penal actions imposed for non-compliance with Regulation 19 of the SEBI (LODR) Regulations, 2015 pertaining to the prior period. The Board further noted that the Company is yet to receive the outcome of its waiver application from NSE.

**Suven Life Sciences Limited**

The Board advised the management to exercise greater diligence in ensuring strict compliance with the provisions of the SEBI (LODR) Regulations, 2015. The Board also recommended seeking external professional advice in cases of ambiguity or uncertainty in the interpretation of the applicable regulations.

Enclosed herewith the following documents: -

- a) Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March, 2026 along with Statement of Assets and Liabilities, Profit & Loss account and Cash Flow Statements.
- b) Auditor's Reports of the Statutory Auditors on the Financial Results
- c) Declaration in respect of Audit Reports with unmodified opinion and
- d) Press Release

Update on patents during this period can be viewed at:  
<https://www.suven.com/Patentupdates.aspx>

The Board Meeting commenced at 12:30 PM (IST) and concluded at 1:30 PM (IST).

This is for your information and records.

Thanking you.

Yours faithfully,

For **Suven Life Sciences Limited**

**K. Sangeetha Laxmi**

Company Secretary and Compliance officer

Encl: as above

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

**SUVEN LIFE SCIENCES LTD**

Regd. Off: SDE Serene Chambers, 6th floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500034  
**STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2026 & UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026**

Rs. In Lakhs

		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2026	31/12/2025	31/03/2025	31/03/2026	31/03/2025
		Refer note.8	Un-Audited	Refer note.8	Audited	Audited
1	<b>Income</b>					
	Revenue from operations	152.01	280.87	146.70	711.47	665.58
	Other Income	677.78	276.59	119.08	1,391.05	1,072.59
	<b>Total income</b>	<b>829.79</b>	<b>557.46</b>	<b>265.78</b>	<b>2,102.52</b>	<b>1,738.17</b>
2	<b>Expenses</b>					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	582.89	626.84	606.61	2,414.94	2,082.49
	d) Finance costs	15.78	-	-	15.78	4.66
	e) Depreciation and amortisation expense	158.25	134.58	134.67	561.35	582.17
	f) R & D Expenses	810.19	590.96	848.73	2,797.24	3,043.16
	g) Other Expenses	379.41	552.25	182.78	1,799.49	733.67
	<b>Total expenses</b>	<b>1,946.52</b>	<b>1,904.63</b>	<b>1,772.79</b>	<b>7,588.80</b>	<b>6,446.15</b>
3	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>(1,116.73)</b>	<b>(1,347.17)</b>	<b>(1,507.01)</b>	<b>(5,486.28)</b>	<b>(4,707.98)</b>
4	<b>Exceptional Items</b>	-	-	-	-	-
5	<b>Profit before Tax (3-4)</b>	<b>(1,116.73)</b>	<b>(1,347.17)</b>	<b>(1,507.01)</b>	<b>(5,486.28)</b>	<b>(4,707.98)</b>
6	<b>Tax Expenses</b>					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-
7	<b>Net Profit/ (Loss) for the period/year(3-4)</b>	<b>(1,116.73)</b>	<b>(1,347.17)</b>	<b>(1,507.01)</b>	<b>(5,486.28)</b>	<b>(4,707.98)</b>
8	<b>Other Comprehensive Income</b>					
8.a	(i) Items that will not be reclassified to profit or loss	(22.45)	3.26	(4.64)	(22.19)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total other Comprehensive Income / (Loss)</b>	<b>(22.45)</b>	<b>3.26</b>	<b>(4.64)</b>	<b>(22.19)</b>	<b>(5.99)</b>
9	<b>Total Comprehensive Income/ (Loss) for the period (5+6)</b>	<b>(1,139.18)</b>	<b>(1,343.91)</b>	<b>(1,511.65)</b>	<b>(5,508.47)</b>	<b>(4,713.97)</b>
10	<b>Paid-up equity share capital</b>	<b>2,637.20</b>	<b>2,274.74</b>	<b>2,180.74</b>	<b>2,637.20</b>	<b>2,180.74</b>
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	<b>Other Equity</b>		-	-	147,699.51	77,770.36
12	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>					
	a) Basic (Based on weighted average no.of shares)	(0.50)	(0.60)	(0.69)	(2.41)	(2.16)
	b) Diluted (Based on weighted average no.of shares)	(0.50)	(0.60)	(0.69)	(2.41)	(2.16)
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



Sl. No.	PARTICULARS	CONSOLIDATED				
		For the Quarter Ended			For the year ended	
		31/03/2026	31/12/2025	31/03/2025	31/03/2026	31/03/2025
		Refer note.8	Un-Audited	Refer note.8	Audited	Audited
1	<b>Income</b>					
	Revenue from operations	152.01	280.87	146.70	711.47	665.58
	Other Income	677.78	277.45	122.25	1,393.01	1,089.69
	<b>Total income</b>	<b>829.79</b>	<b>558.32</b>	<b>268.95</b>	<b>2,104.48</b>	<b>1,755.27</b>
2	<b>Expenses</b>					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	582.89	626.84	606.61	2,414.94	2,082.49
	d) Finance costs	15.78	-	-	15.78	4.66
	e) Depreciation and amortisation expense	158.25	134.58	134.67	561.35	582.17
	f) R & D Expenses	4,233.12	9,404.72	3,732.50	24,818.81	14,396.18
	g) Other Expenses	399.30	584.36	189.66	1,928.01	764.27
	<b>Total expenses</b>	<b>5,389.34</b>	<b>10,750.50</b>	<b>4,663.44</b>	<b>29,738.89</b>	<b>17,829.77</b>
3	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>(4,559.55)</b>	<b>(10,192.18)</b>	<b>(4,394.49)</b>	<b>(27,634.41)</b>	<b>(16,074.50)</b>
4	<b>Exceptional Items</b>	-	-	-	-	-
5	<b>Profit before Tax (3-4)</b>	<b>(4,559.55)</b>	<b>(10,192.18)</b>	<b>(4,394.49)</b>	<b>(27,634.41)</b>	<b>(16,074.50)</b>
4	<b>Tax Expenses</b>					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-
5	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>(4,559.55)</b>	<b>(10,192.18)</b>	<b>(4,394.49)</b>	<b>(27,634.41)</b>	<b>(16,074.50)</b>
6	<b>Other Comprehensive Income</b>					
6.a	(i) Items that will not be reclassified to profit or loss	(22.45)	3.26	(4.64)	(22.19)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
6.b	(i) Items that will be reclassified to profit or loss	(24.21)	(78.39)	(52.34)	(96.20)	(52.34)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total other Comprehensive Income / (Loss)</b>	<b>(46.66)</b>	<b>(75.13)</b>	<b>(56.98)</b>	<b>(118.39)</b>	<b>(58.33)</b>
7	<b>Total Comprehensive Income/ (Loss) for the period (5+6)</b>	<b>(4,606.21)</b>	<b>(10,267.31)</b>	<b>(4,451.47)</b>	<b>(27,752.80)</b>	<b>(16,132.83)</b>
8	<b>Paid-up equity share capital Face Value of the Share</b>	<b>2,637.20</b> Re.1.00	<b>2,274.74</b> Re.1.00	<b>2,180.74</b> Re.1.00	<b>2,637.20</b> Re.1.00	<b>2,180.74</b> Re.1.00
9	<b>Other Equity</b>	-	-	-	56,502.76	8,817.94
10	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>					
	a) Basic (Based on weighted average no.of shares)	(2.02)	(4.55)	(2.02)	(12.13)	(7.37)
	b) Diluted(Based on weighted average no.of shares)	(2.02)	(4.55)	(2.02)	(12.13)	(7.37)
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)

**SUVEN LIFE SCIENCES LTD**

Regd. Off: SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500034



**Statement of Assets & Liabilities**

Rs. in Lakhs

Particulars	Standalone as at		Consolidated as at	
	31/03/2026	31/03/2025	31/03/2026	31/03/2025
<b>A ASSETS</b>				
<b>1 Non-current assets</b>				
(a) Property, Plant and Equipment	5,570.33	5,947.19	5,570.33	5,947.19
(b) Capital Work-in-Progress	359.60	0.97	359.60	0.97
(c) Other Intangible Assets	14.47	18.08	14.47	18.08
(d) Right of use Assets	1,714.74	-	1,714.74	-
(e) Financial Assets				
I. Investments	91,284.63	69,147.16	-	-
II. Other financial assets	87.50	4.86	87.50	4.86
(f) Other Non-current Assets	3.88	-	3.88	-
<b>Total Non-Current assets</b>	<b>99,035.15</b>	<b>75,118.26</b>	<b>7,750.52</b>	<b>5,971.10</b>
<b>2 Current assets</b>				
<b>Inventories</b>	<b>10.20</b>	<b>23.75</b>	<b>10.20</b>	<b>23.75</b>
(a) Financial Assets				
I. Investments in mutual funds	18,065.16	2,227.85	18,065.16	2,227.85
II. Trade Receivables	150.84	133.64	150.84	133.64
III. Cash and Cash equivalents	228.13	46.35	827.91	1,502.55
IV. Bank balances other than (III) above	32,917.70	1,950.00	32,917.70	2,270.08
V. Other financial assets	370.31	7.60	370.31	7.60
(b) Current Tax asset (net)	194.92	119.00	194.92	119.00
(c) Other current assets	2,133.84	1,262.76	2,133.84	1,262.76
<b>Total Current assets</b>	<b>54,071.10</b>	<b>5,770.95</b>	<b>54,670.88</b>	<b>7,547.23</b>
<b>TOTAL - ASSETS</b>	<b>153,106.25</b>	<b>80,889.21</b>	<b>62,421.40</b>	<b>13,518.33</b>
<b>B EQUITY AND LIABILITIES</b>				
<b>1 EQUITY</b>				
(a) Equity Share Capital	2,637.21	2,180.74	2,637.21	2,180.74
(b) Other Equity	147,699.51	77,770.36	56,502.76	8,817.94
<b>Total Equity</b>	<b>150,336.72</b>	<b>79,951.10</b>	<b>59,139.97</b>	<b>10,998.68</b>
<b>2 LIABILITIES</b>				
<b>Non-current liabilities</b>				
Provision for Employee benefits	191.74	171.05	191.74	171.05
<b>Total non-current liabilities</b>	<b>191.74</b>	<b>171.05</b>	<b>191.74</b>	<b>171.05</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
I. Lease Liabilities	1,669.42	-	1,669.42	-
II. Trade payables				
a) To Micro & Small Enterprises	36.33	38.42	36.33	38.42
b) Other than Micro & Small Enterprises	444.99	484.24	444.99	484.24
III. Other Financial Liabilities	52.09	20.07	563.99	1,601.61
(b) Provision Employee benefits	152.37	164.05	152.37	164.05
(c) Other Current liabilities	222.59	60.28	222.59	60.28
<b>Total - Current liabilities</b>	<b>2,577.79</b>	<b>767.06</b>	<b>3,089.69</b>	<b>2,348.60</b>
<b>Total Liabilities</b>	<b>2,769.53</b>	<b>938.11</b>	<b>3,281.43</b>	<b>2,519.65</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>153,106.25</b>	<b>80,889.21</b>	<b>62,421.40</b>	<b>13,518.33</b>

Place : Hyderabad  
Date : May 13, 2026

For SUVEN LIFE SCIENCES LTD

*Venkat Jasti*

**VENKAT JASTI**  
Chairman & MD  
DIN: 00278028



SUVEN LIFE SCIENCES LIMITED

Standalone Statement of Cash flows for the year ended 31st March, 2026

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	(5,486.29)	(4,707.98)
Adjustments :		
Depreciation and amortisation expense	561.35	530.71
ESOP expenses	178.69	127.45
Interest Income	(422.92)	(557.32)
Finance Cost	15.78	4.66
Lease payment	(37.25)	-
interest on security deposit(116)	(0.75)	-
Foreign exchange loss/(profit)	24.23	-
Gain on Unrealised Current Investment	(953.70)	(497.56)
<b>Operating profit before working capital changes</b>	<b>(6,120.86)</b>	<b>(5,100.04)</b>
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(17.20)	(5.05)
Inventories	13.55	47.10
Other non current assets	(3.88)	52.05
Other current assets	(871.08)	(186.01)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(65.56)	315.85
Long term provisions	20.69	36.45
Short term provision	(33.87)	46.40
Other financial liabilities	32.02	(15.77)
Other current liabilities	162.31	9.44
<b>Cash generated from operating activities</b>	<b>(6,883.88)</b>	<b>(4,799.58)</b>
Income taxes paid (net of refunds)	75.91	(60.51)
<b>Net Cash flows from operating activities</b>	<b>(6,959.79)</b>	<b>(4,739.07)</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(508.34)	(3,727.58)
Other financial assets	(499.64)	209.22
Interest received	422.92	557.32
Changes in Investments	(22,137.47)	(11,435.81)
Sale/(purchase) of mutual funds	(14,883.61)	5,863.22
Bank balances not considered as cash and cash equivalents	(30,967.70)	12,954.71
<b>Net cash flow from /( used in) investing activities</b>	<b>(68,573.84)</b>	<b>4,421.08</b>
<b>C. Cash flows from financing activities</b>		
Proceeds from Issue of Equity shares and related reserves	75,715.41	-
Changes In Lease Liability	-	(70.97)
Finance Cost	-	(4.66)
<b>Net cash flow from /(used In) financing activities</b>	<b>75,715.41</b>	<b>(75.63)</b>
Net increase/(decrease) in cash and cash equivalents	181.78	(393.62)
Cash and cash equivalents as at the beginning of the year	46.35	439.97
<b>Cash and cash equivalents at the end of the year</b>	<b>228.13</b>	<b>46.35</b>
Cash and cash equivalents	228.13	46.35
<b>Balances per statement of cash flows</b>	<b>228.13</b>	<b>46.35</b>

For SUVEN LIFE SCIENCES LTD

*Venkata Jasti*

VENKAT JASTI  
Chairman & MD  
DIN: 00278028

Place : Hyderabad  
Date : May 13, 2026



**SUVEN LIFE SCIENCES LIMITED**

**Consolidated Statement of Cash flows for the year ended 31st March,2026**

*(All amounts in Indian Rupees In Lakhs, unless otherwise stated)*

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	(27,634.41)	(16,074.50)
<b>Adjustments :</b>		
Depreciation and amortisation expense	561.35	530.71
ESOP expenses	178.69	127.45
Interest Income	(424.03)	(568.25)
Finance Cost	15.78	4.66
Lease payment	(37.25)	-
interest on security deposit(116)	(0.75)	
Foreign exchange loss/(profit)	24.23	
Gain on Unrealised Current Investment	(953.71)	(497.56)
<b>Operating profit before working capital changes</b>	<b>(28,270.10)</b>	<b>(16,477.49)</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	(17.20)	(5.05)
Inventories	13.55	47.10
Other non current assets	(3.88)	52.05
Other current assets	(871.08)	(186.01)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	(65.56)	315.85
Long term provisions	20.69	36.45
Short term provision	(33.87)	46.40
Other financial liabilities	(1,037.62)	690.29
Other current liabilities	162.31	9.44
<b>Cash generated from operating activities</b>	<b>(30,102.76)</b>	<b>(15,470.97)</b>
Income taxes paid (net of refunds)	75.91	(60.51)
<b>Net Cash flows from operating activities</b>	<b>(30,178.67)</b>	<b>(15,410.46)</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(508.34)	(3,727.58)
Other financial assets	(499.64)	209.22
Interest received	424.03	568.25
Sale/(purchase) of mutual funds	(14,883.61)	5,863.22
Foreign currency translation reserve	(96.20)	(52.34)
Bank balances not considered as cash and cash equivalents	(30,647.62)	12,634.63
<b>Net cash flow from /( used in) investing activities</b>	<b>(46,211.38)</b>	<b>15,495.40</b>
<b>C. Cash flows from financing activities</b>		
Proceeds from Issue of Equity shares and related reserves	75,715.41	-
Changes In Lease Liability	-	(70.97)
Finance Cost	-	(4.66)
<b>Net cash flow from /(used In) financing activities</b>	<b>75,715.41</b>	<b>(75.63)</b>
Net increase/(decrease) in cash and cash equivalents	(674.64)	9.31
Cash and cash equivalents as at the beginning of the year	1,502.55	1,493.24
<b>Cash and cash equivalents at the end of the year</b>	<b>827.91</b>	<b>1,502.55</b>
Cash and cash equivalents	827.91	1,502.55
<b>Balances per statement of cash flows</b>	<b>827.91</b>	<b>1,502.55</b>

For SUVEN LIFE SCIENCES LTD

*Venkata Jasti*  
**VENKAT JASTI**  
 Chairman & MD  
 DIN: 00278028

Place : Hyderabad  
 Date : May 13, 2026



**NOTES:-**

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 13, 2026. The results for the year ended March 31, 2026 has been audited and for the quarter ended March 31, 2026 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc.

4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5.1) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination & Remuneration Committee on May 6, 2024.

5.2) ESOP: for the quarter ended March 31, 2026, the Company recognized an employee benefit expense (EBP) of Rs. 99.25 lakhs in accordance with Ind AS 102 – Share-based Payment. The cumulative EBP recognized as of March 2026 amounts to Rs.178.69 lakhs.

6) Preferential Issue: The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025.

Each warrant is convertible into one equity share of face value ₹1/- at an exercise price of ₹134/- per share, within a period of 18 months from the date of allotment.

Out of the Issue proceeds of Rs.85,764 Lakhs, Rs.76433 Lakhs has been received and Rs. 9331Lakhs is yet to be received from warrant holders. During the period from July'25 to March'26 the Company has allotted 45432866 equity shares on a preferential basis upon conversion of equivalent number of fully paid warrants to six allottees, upon receipt of 100% of the warrant consideration amounting to Rs.60,880.04 lakhs.

Summary of Utilisation of Proceeds of Preferential issue as on 31.03.2026

Particulars	Rs.In lakhs
Amount Received through Preferential Issue	76,432.53
Less: Amount Utilised	26,068.64
<b>Balance Amount</b>	<b>50,363.89</b>

7) Impact of Labour Codes:

On November 21,2025, the government of India notified provisions of the new Labour Code (4 Labour codes) which consolidates 29 existing labour laws into a unified framework governing employee benefit. The labour codes, amongst other things, introduced changes including a uniform definition of wages and enhanced benefits relating to leave. The group has assessed the financial implications of these changes which had resulted in increase in gratuity liability arising out of past service cost by Rs.36.34 lakhs as at 31st Dec,2026 out of total Rs. 61.15 lakhs, for the year ended 31 March,2026.

The Group is in the process of evaluating the impact of other provisions of the Labour Codes, if any, and will recognise the same as and when such impact becomes reasonably ascertainable.

8) The figures for the current quarter and quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and March 31, 2025, respectively and published year to date figures upto 3rd quarter ended 31st December 2025 and 31st December 2024, respectively, regrouped as necessary.

Place : Hyderabad  
Date: May 13, 2026



For SUVEN LIFE SCIENCES LTD

*Venkata Jasti*

VENKAT JASTI  
Chairman & MD  
DIN: 00278028

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED  
 FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**To**  
**The Board of Directors of**  
**Suven Life Sciences Limited**

**Opinion and Conclusion**

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2026 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2026 (refer "Other Matters" section below), which were subject to limited review by us, both included in the accompanying "Statement of Audited Consolidated Financial Results for the Year Ended March 31, 2026 and Unaudited Consolidated Financial Results for the Quarter Ended March 31, 2026" of **Suven Life Sciences Limited** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") for the quarter and year ended March 31, 2026, (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

**1) Opinion on Annual Consolidated Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial information of subsidiaries referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2026:


a) includes the results of the following entities:

<b>Name of the Company</b>	<b>Country</b>	<b>Relationship</b>
SUVEN NEUROSCIENCES INC	USA	Wholly Owned Subsidiary

- b) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- c) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net loss and consolidated total comprehensive loss and other financial information of the Group for the year ended March 31, 2026.

**2) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026**

With respect to the Consolidated Financial Results for the quarter ended March 31, 2026, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit reports for the year ended March 31, 2026 of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2026, prepared in accordance with the



13-05-2026

recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

### **Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026**

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under Section 143(10) of the Companies Act, 2013 (the “Act”). Our responsibilities under those Standards are further described in paragraph(a) of Auditor’s Responsibilities section below. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

### **Management’s and Board of Director’s Responsibilities for the Statement**

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent’s Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2026, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the consolidated net loss and consolidated other comprehensive loss and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.



13-05-2026

## **Auditor's Responsibilities for**


### **(a) Audit of the Consolidated Financial Results for the year ended March 31, 2026**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Information of the entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of entities

13-05-2026



included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2026**


We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a) of Opinion and Conclusion section above.

As part of annual audit we also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

**Other Matters**

- Attention is drawn to Note 8 to the Statement which states that the Consolidated Financial Results includes the results for the Quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year of the financial results which were subject to limited review by us. Our report is not modified in respect of this matter.
- Attention is drawn to Note 8 to the Statement, the figures for the corresponding quarter ended March 31, 2025 are the balancing figures between the annual audited figures for the year then ended and the year-to-date figures for the 9 months period ended December 31, 2024. We have not issued separate limited review report on the results



13-05-2026

and figures for the quarter ended March 31, 2025. Our report is not modified in respect of this matter.

- We did not audit financial information of subsidiary included in the consolidated financial results, whose financial information reflect total assets of Rs. 599.78 lakhs as at March 31, 2026 and total revenues of Rs.0.01 lakhs and Rs.1.97 lakhs for the quarter and year ended March 31, 2026 respectively, total net loss after tax of Rs.(3,442.81) lakhs and Rs.(22,148.12) lakhs for the quarter and year ended March 31, 2026 respectively and total comprehensive Loss of Rs.(3,467.02) lakhs and Rs.(22,244.33) Lakhs for the quarter and year ended March 31, 2026 respectively and net cash inflows of Rs.(856.42) lakhs for the year ended March 31, 2026, as considered in the Statement. This financial information has been audited, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

**For M/s. KARVY & CO**

Chartered Accountants

(Firm Registration No .001757S)



**AJAYKUMAR KOSARAJU**

Partner

M.No. 021989

UDIN:26021989KNCWDK3392

Place: Hyderabad

Date: 13-05-2026



13-05-2026

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE  
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**To**  
**The Board of Directors of**  
**Suven Life Sciences Limited**

**Opinion and Conclusion**

We have (a) audited the Standalone Financial Results for the year ended March 31, 2026 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below) which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Year Ended March 31, 2026 and unaudited Standalone Financial Results for the Quarter Ended March 31, 2026 ("the Statement") of **Suven Life Sciences Limited** ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Standalone Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:

- i. Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net loss and total comprehensive loss and other financial information of the Company for the year then ended.

**(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended  
March 31, 2026**

With respect to the Standalone Financial Results for the quarter ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



13-05-2026

## **Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026**

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under Section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in paragraph (a) of Auditor’s Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“the ICAI”) together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

### **Management’s Responsibilities for the Statement**

This Statement which includes the Standalone Financial Results is the responsibility of the Company’s Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net loss and other comprehensive loss and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company’s ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

### **Auditors Responsibilities**

#### **(a) Audit of the Standalone Financial Results for the year ended March 31, 2026**

Our objective is to obtain reasonable assurance whether the Standalone Financial Results for the year ended March 31, 2026 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be

13-05-2026



expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.



13-05-2026

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, and any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


**(b) Review of the Standalone Financial Results for the quarter ended March 31, 2026**

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements (“SRE”) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Other Matters**

- Attention is drawn to Note 8 to the Statement which states that the Standalone Financial Results includes the results for the Quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the statement is not modified in respect of this matter.
- Attention is drawn to Note 8 to the Statement, the figures for the corresponding quarter ended March 31, 2025 are the balancing figures between the annual audited figures for the full financial year then ended and the year-to-date figures for the 9 months period ended December 31, 2024. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2025. Our report is not modified in respect of this matter.

**For M/s. KARVY & CO.,**  
Chartered Accountants  
(Firm Regn. No.001757S)

  
**AJAYKUMAR KOSARAJU**  
Partner  
M.No. 021989  
UDIN: 26021989JRFRHX3651



Place: Hyderabad  
Date :13-05-2026

13-05-2026

SUVEN/NSE&BSE/AFR/2026-27

**Date:** May 13, 2026

**To**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Regulation 33(3) of the SEBI (LODR) Regulations, 2015 – Declaration in respect of Audit Reports with unmodified opinion for the financial year ended 31st March 2026**

.....

We hereby declare that the Statutory Auditors of the Company, M/s. KARVY & Co., Chartered Accountants have issued an Audit Reports with unmodified opinion on Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31st March, 2026.

We request you to take this document on your record.

Thanking you,  
Yours faithfully,

**For Suven Life Sciences Limited**

Venkateswarlu Jasti  
Chairman & MD

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

## News Release

**HYDERABAD, INDIA (13 May 2026)** – SUVEN Life Sciences Limited ("Suven") today announced audited financial results for the quarter and year ended 31 Mar 2026. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13 May 2026 at Hyderabad.

### CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Year ended	
	31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
Revenue	82.98	55.83	26.90	210.45	175.53
R&D and Operational expenses	521.53	1,061.59	452.88	2,916.18	1,724.29
Depreciation and Amortisation	15.83	13.46	13.47	56.14	58.22
Finance cost	1.58	-	-	1.58	0.47
Total expenses	538.93	1,075.05	466.34	2,973.89	1,782.98
Exceptional items (insurance claim received)	-	-	-	-	-
Tax	-	-	-	-	-
Profit/(Loss) After Tax for the period/year	(455.96)	(1,019.22)	(439.45)	(2,763.44)	(1,607.45)
Other comprehensive income	(4.67)	(7.51)	(5.70)	(11.84)	(5.83)
Total comprehensive income	(460.62)	(1,026.73)	(445.15)	(2,775.28)	(1,613.28)
Paid up equity capital	263.72	227.47	218.07	263.72	218.07
Earnings per share of Rs.1 each (EPS)	(2.02)	(4.55)	(2.02)	(12.13)	(7.37)

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Achieves 76% Enrollment milestone in Global Phase 3 Trial for Agitation in Alzheimer's Dementia. "This milestone reflects continued momentum in the program, completion of patient enrolment by end of calendar 2026 is certain if not earlier and last patient last visit will be in quarter 1, 2027 enabling progression towards database lock and reporting of results potentially in Q2/Q3 - 2027 calendar year.
- SUVN-G3031 (Samelisant) – Initiated Global Phase 3 clinical study for treatment of EDS in Narcolepsy in April 2026.
- SUVN-911 (Ropanicant) – Phase 2B clinical study in USA is complete. Data read out expected soon.
- SUVN-D4010 (Usmarapride) – New IND submission done with FDA for Phase-2 POC (proof of concept) for the "Treatment of cognitive dysfunction in adults with major depressive disorder (MDD) and Phase 2 double blind study will start during calendar 2026.
- SUVN-I6107 – Phase 1 study for establishing safety and pharmacokinetics completed and now preparing for Phase 2 clinical study.

(d) Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 7 patents during the period covering countries ARIPO, EPO, Japan and Mexico.

[For more information on Suven please visit our Web site at http://www.suven.com](http://www.suven.com)

#### Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com